FBI局长低调访华，单方面宣布达成共识，商务部宣布新增13项管制

Core Points - The FBI Director Patel's visit to China was low-key, and he announced a consensus with China to stop the flow of fentanyl-related chemicals [1][3] - China's response to Patel's visit was cautious, with no confirmation or denial of the visit, highlighting a difference in diplomatic approaches [3][6] - The U.S. has politicized the fentanyl issue, which is primarily an internal crisis, using it as a diplomatic tool against China [8] Group 1 - The U.S. Department of Commerce announced new export controls on 13 types of chemicals, many of which are key precursors for synthetic fentanyl, targeting the U.S., Mexico, and Canada [3] - China has established a strict regulatory system for fentanyl since 2019, indicating that the U.S. fentanyl crisis should not be blamed on China but rather on U.S. regulatory failures [6][9] - The U.S. media has pointed out that China holds significant control over the pharmaceutical supply chain, which could be leveraged against the U.S. [8] Group 2 - China has maintained a responsible attitude by controlling the export of relevant items and has not taken actions to "choke" the U.S. in the pharmaceutical sector [9][10] - During the COVID-19 pandemic, China ensured a sufficient supply of medical supplies to the U.S., exporting over 37.7 billion masks and significant quantities of other medical equipment [10]